{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:24:57Z","timestamp":1787142297892,"version":"build-2736575974"},"reference-count":31,"publisher":"American Chemical Society (ACS)","issue":"8","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"crossref","award":["2025ZDZX0046"],"award-info":[{"award-number":["2025ZDZX0046"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gansu Isotope Laboratory","award":["GSTWS2501"],"award-info":[{"award-number":["GSTWS2501"]}]},{"name":"Luzhou Science and Technology Program","award":["2025LZXNYDJC04"],"award-info":[{"award-number":["2025LZXNYDJC04"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>To improve the theranostic efficacy of PSMA-targeted radiopharmaceuticals on patients with medium-to-low PSMA expression, we radiolabeled a series of novel designed PSMA-targeting dimer agents to improve tumor imaging and treatment outcomes under challenging conditions. All agents were successfully radiolabeled with 68Ga in moderate decay-corrected labeling yield and high radiochemical purity. Among them, [68Ga]Ga-TVS-PSMA-1 exhibited high tumor uptake in both LNCaP and 22RV1 models. [177Lu]Lu-TVS-PSMA-1 demonstrated significantly improved treatment efficacy with a lower dose and good safety profile compared with [177Lu]Lu-PSMA-617. A first-in-human [68Ga]Ga-TVS-PSMA-1 PET\/CT scan was performed in a 66-year-old male prostate cancer patient. Two metastatic lesions in the lumbar vertebrae were clearly visualized, and the primary tumor exhibited an SUVmax of 30.3. The [68Ga]Ga-TVS-PSMA-1 showed lower salivary gland uptake compared with previously reported values for [68Ga]Ga-PSMA-11; however, confirmation in larger patient cohorts is required. This study demonstrates that the dimer agent TVS-PSMA-1 holds great potential as a next-generation theranostic agent for prostate cancer.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00211","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:09:51Z","timestamp":1784272191000},"page":"1633-1642","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical\nEvaluation in Animals for the Efficacy,\nDosimetry, and Safety of [68Ga]Ga\/[177Lu]Lu-TVS-PSMA\nRadioligands, and First-in-Human Study of [68Ga]Ga-TVS-PSMA-1"],"prefix":"10.1021","volume":"37","author":[{"given":"Yuduo","family":"Wan","sequence":"first","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]},{"name":"Southwest Medical University , , , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlu","family":"Feng","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Sun","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyu","family":"Chen","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of North Carolina , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyuan","family":"Ding","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1063-0298","authenticated-orcid":true,"given":"Zibo","family":"Li","sequence":"additional","affiliation":[{"name":"University of North Carolina , , , ,","place":["Chapel Hill, North Carolina, United States, 27599"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0284-5958","authenticated-orcid":true,"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Southwest Medical University , , No. 25 Taiping St , Jiangyang District, , ,","place":["Luzhou, Sichuan, China, 646000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"3","key":"2026081907211158300_cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"GLOBOCAN estimates of incidence and\nmortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"11","key":"2026081907211158300_cit2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","article-title":"Development and\nprevalence of castration-resistant\nprostate cancer subtypes","volume":"22","author":"Vellky","year":"2020","journal-title":"Neoplasia"},{"key":"2026081907211158300_cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy\nand drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resistance Updates"},{"issue":"3","key":"2026081907211158300_cit4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2967\/jnumed.118.214403","article-title":"Evaluation of 111In-DOTA-5D3, a surrogate\nSPECT imaging agent for radioimmunotherapy of prostate-specific membrane\nantigen","volume":"60","author":"Banerjee","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026081907211158300_cit5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2967\/jnumed.118.220715","article-title":"Phase I study of CTT1057, an 18F-labeled imaging agent with phosphoramidate core targeting\nprostate-specific membrane antigen in prostate cancer","volume":"60","author":"Behr","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026081907211158300_cit6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11307-021-01632-x","article-title":"Translational\ndevelopment of a Zr-89-labeledInhibitor\nof prostate-specifc membrane antigen for PET imaging in prostate cancer","volume":"24","author":"Va\u0301zquez","year":"2022","journal-title":"Mol. Imaging Biol."},{"issue":"3","key":"2026081907211158300_cit7","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients\nwith biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026081907211158300_cit8","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617\n(PluvictoTM): The first\nFDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"14","key":"2026081907211158300_cit9","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-21-4531","article-title":"Prostate-specific membrane\nantigen expression and response to DNA damaging agents in prostate\ncancer","volume":"28","author":"Sheehan","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"2026081907211158300_cit10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German\nmulticenter study investigating 177Lu-PSMA-617 radioligand\ntherapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026081907211158300_cit11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2967\/jnumed.122.265099","article-title":"PSMA-negative lesion progression\nunder 177Lu-PSMA radioligand\ntherapy","volume":"64","author":"Murthy","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026081907211158300_cit12","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1078-0432.CCR-19-1485","article-title":"Investigating\nPSMA-targeted radioligand therapy efficacy as a function of cellular\nPSMA levels and intratumoral PSMA heterogeneity","volume":"26","author":"Current","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"2026081907211158300_cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102941","article-title":"Current and future directions in\ntheranostics for neuroendocrine prostate cancer","volume":"136","author":"Bilgin","year":"2025","journal-title":"Cancer Treat Rev."},{"issue":"Supplement 1","key":"2026081907211158300_cit14","article-title":"Engineering\na novel multi-arm vinyl sulfone functionalized core for\ntheranostic applications","volume":"66","author":"Zhang","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"12","key":"2026081907211158300_cit15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2967\/jnumed.119.226993","article-title":"Molecular imaging of fibroblast activity\nafter myocardial infarction using a 68Ga-labelled fibroblast\nactivation protein inhibitor FAPI-04","volume":"60","author":"Varasteh","year":"2019","journal-title":"J. Nucl.\nMed."},{"issue":"6","key":"2026081907211158300_cit16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations\nfor dosimetry of 177Lu-labelled somatostatin-receptor-\nand PSMA-targeting ligands","volume":"49","author":"Sjo\u0308green Gleisner","year":"2022","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"issue":"11","key":"2026081907211158300_cit17","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing\ntreatment efficacy of 177Lu-PSMA-617 with the conjugation\nof an albumin-binding motif: Preclinical dosimetry and endoradiotherapy\nstudies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol. Pharm."},{"issue":"8","key":"2026081907211158300_cit18","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s00259-023-06155-x","article-title":"[177Lu]Lu-PSMA-617 theranostic\nprobe for hepatocellular\ncarcinoma imaging and therapy","volume":"50","author":"Lu","year":"2023","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"11","key":"2026081907211158300_cit19","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1097\/RLU.0000000000004353","article-title":"Comparison\nof internal dosimetry\nof 18F-PSMA-1007 and 68Ga-PSMA-11-HBED-CC","volume":"47","author":"Sharma","year":"2022","journal-title":"Clin Nucl. Med."},{"issue":"2","key":"2026081907211158300_cit20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/MNM.0000000000001506","article-title":"Reduction of radiation\naccumulation in salivary glands through oral vitamin C during 68Ga-PSMA-11 total-body dynamic PET\/CT imaging","volume":"43","author":"Yu","year":"2022","journal-title":"Nucl. Med. Commun."},{"issue":"3","key":"2026081907211158300_cit21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.3390\/curroncol31030106","article-title":"(177)Lu-PSMA-617\nin metastatic castration-resistant prostate cancer: A review of the\nevidence and implications for canadian clinical practice","volume":"31","author":"Chi","year":"2024","journal-title":"Curr. Oncol."},{"issue":"2","key":"2026081907211158300_cit22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.remn.2017.05.004","article-title":"Value of post-therapy\n177Lu-PSMA images for accurate interpretation\nof therapy response with 68Ga-PSMA PET\/CT","volume":"37","author":"Tuncel","year":"2018","journal-title":"Rev.\nEsp Med. Nucl. Imagen Mol."},{"issue":"11","key":"2026081907211158300_cit23","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1007\/s00259-024-06754-2","article-title":"Chelator boosted tumor-retention and pharmacokinetic\nproperties:\ndevelopment of 64Cu labeled radiopharmaceuticals targeting\nneurotensin receptor","volume":"51","author":"Zhang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"issue":"4","key":"2026081907211158300_cit24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00259-024-07000-5","article-title":"Real-time diagnosis\nof sampled lesions in targeted biopsy of prostate\ncancer using a novel tracer [(64)Cu]Cu-DOTA-PSMA-3Q: a pilot preclinical\nstudy","volume":"52","author":"Zhang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026081907211158300_cit25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1874471008666150312160440","article-title":"Chemistry and bifunctional\nchelating agents for binding (177)Lu","volume":"8","author":"Parus","year":"2015","journal-title":"Curr.\nRadiopharm."},{"issue":"8","key":"2026081907211158300_cit26","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081926","article-title":"Salivary gland toxicity\nof PSMA-targeted radioligand\ntherapy with (177)Lu-PSMA and combined (225)Ac- and (177)Lu-labeled\nPSMA ligands (TANDEM-PRLT) in advanced prostate cancer: A single-center\nsystematic investigation","volume":"12","author":"Langbein","year":"2022","journal-title":"Diagnostics"},{"issue":"4","key":"2026081907211158300_cit27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant\nprostate cancer: Correlations between pretherapeutic imaging and whole-body\ntumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J.\nNucl. Med."},{"issue":"3","key":"2026081907211158300_cit28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00259-022-05982-8","article-title":"Cross-reactivity\nto\nglutamate carboxypeptidase III causes undesired salivary gland and\nkidney uptake of PSMA-targeted small-molecule radionuclide therapeutics","volume":"50","author":"Lucaroni","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"18","key":"2026081907211158300_cit29","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1039\/D3SC06668A","article-title":"DNA-encoded chemical\nlibraries enable\nthe discovery of potent PSMA-ligands with substantially reduced affinity\ntowards the GCPIII anti-target","volume":"15","author":"Lucaroni","year":"2024","journal-title":"Chem. Sci."},{"issue":"1","key":"2026081907211158300_cit30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-06393-z","article-title":"Characterizing PSMA\nheterogeneity in prostate cancer and identifying\nclinically actionable tumor associated antigens in PSMA negative cases","volume":"15","author":"Mulati","year":"2025","journal-title":"Sci. Rep."},{"issue":"12","key":"2026081907211158300_cit31","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"VISION Investigators. Lutetium-177-PSMA-617 for Metastatic\nCastration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl\nJ. Med."}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00211","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1633\/65987505\/acs.bioconjchem.6c00211.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/8\/1633\/65987505\/acs.bioconjchem.6c00211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T11:32:53Z","timestamp":1787139173000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/8\/1633\/5212681\/Preclinical-Evaluation-in-Animals-for-the-Efficacy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,7,17]]},"published-print":{"date-parts":[[2026,8,19]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00211","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}